Previous Article | Next Article 
Journal of Virology, December 1998, p. 10298-10300, Vol. 72, No. 12
Division of Molecular Genetics,
Received 29 June 1998/Accepted 15 September 1998
Lack of permissive and productive cell cultures for the human
papillomaviruses (HPVs) has hindered the study of virus-neutralizing antibodies and infection. We developed a cell-free system generating infectious HPV16 pseudovirions. HPV16 L1/L2 capsids, which had been
self-assembled in insect cells (Sf9) expressing virion proteins L1 and
L2, were disassembled with 2-mercaptoethanol (2-ME), a reducing agent,
and reassembled by removal of 2-ME in the presence of a
Human papillomaviruses (HPVs), which
cause a variety of proliferating epithelial lesions including skin and
cervical cancers, are classified into more than 70 types based on
nucleotide sequence homology of viral DNA. Despite overall similarity
in genomic organization, HPVs have rather diverse tissue specificities
and malignant potentials (5, 13). Therefore, analyses of
antigenic relationships among HPVs are needed to study viral
pathogenicity and to develop a prophylactic vaccine strategy. Studies
on neutralizing antibodies against HPVs have been hampered by the lack
of cell culture systems for producing HPV particles and for monitoring
infection with HPVs.
In order to overcome this problem, methods have been devised
(9-11) to encapsidate DNA into L1/L2 capsids, which are
self-assembled particles in eukaryotic cells infected with recombinant
viruses, for expression of major (L1) and minor (L2) structural
proteins of HPVs (1, 3). Pseudovirions of HPV16 were
generated in hamster BPHE-1 cells by using a recombinant Semliki Forest
virus (9), and those of HPV33 were produced in monkey COS-1
cells by using a recombinant vaccinia virus (10). These
studies indicated that L2 is required for efficient encapsidation of
DNA and that specific DNA sequences are not required for packaging
(12). Infection of cells with pseudovirions is neutralized by anti-L1
antiserum in a type-specific manner (9, 10). In this report,
we describe the encapsidation of plasmid DNA into HPV16 L1/L2 capsids
in a cell-free system, producing infectious pseudovirions in vitro.
HPV16 L1/L2 capsids that had been disassembled with the reducing agent
2-mercaptoethanol (2-ME) were allowed to reassemble by the removal of
2-ME (4, 7) in the presence of closed circular (form I) plasmid DNA of
pSV/ Virion proteins L1 and L2 in the fractions were assayed by
enzyme-linked immunosorbent assay (ELISA). Aliquots (1 µl) from the
fractions were incubated in a carbonate buffer (pH 9.6) for 16 h
at 4°C to disrupt capsids and fixed in wells of ELISA plates. L1 and
L2 were detected by using mouse antibodies against HPV-16 L1 or L2, as
described previously (2). Distributions of L1 and L2 in the
gradient are shown in Fig. 1A. The L1
distribution showed two peaks around fractions 13 and 19, whereas the
L2 distribution had less-distinctive peaks. Fractions 11 to 14, containing both L1 and L2, corresponded to a density of 1.31 g/ml in
the gradient.
The presence of plasmid DNA in the selected fractions was examined by
PCR with primers specific for the Electron microscopy confirmed the presence of pseudovirions in fraction
13 (Fig. 2). Particles purified from Sf9
cells expressing L1 and L2 (Fig. 2A) were broken down to the level of
capsomeres (Fig. 2B), from which particles were reassembled (Fig. 2C).
The reassembled capsids were morphologically similar to the particles assembled in Sf9 cells. The concentration of the reassembled capsids was estimated from the amount of L1 protein in fraction 13. Approximately 10 µg of pseudovirions were obtained from 1 mg of
disassembled capsids.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
In Vitro Construction of Pseudovirions of Human
Papillomavirus Type 16: Incorporation of Plasmid DNA into
Reassembled L1/L2 Capsids
ABSTRACT
Top
Abstract
Text
References
-galactosidase expression plasmid. Plasmid DNA purified together
with the reassembled capsids was resistant to DNase I digestion. The
reassembled pseudovirions mediated DNA transfer to COS-1 cells, as
monitored by induced -galactosidase activity. Transfer was inhibited
by anti-HPV16 L1 antiserum but not by antisera against L1s of HPV6 and
HPV18. Construction in vitro of HPV pseudovirions containing marker
plasmids would be potentially useful in developing methods to assay
virus-neutralizing antibodies and to transfer exogenous genes to
HPV-susceptible cells.
TEXT
Top
Abstract
Text
References
-gal (Promega Corp., Madison, Wis.), an expression plasmid (6.8 kb) for -galactosidase, purified by the ethidium bromide-CsCl
buoyant density method (8). The L1/L2 capsids produced in
Sf9 cells infected with recombinant baculovirus capable of expressing
HPV16 L1 and L2 were purified by CsCl equilibrium density gradient
centrifugation, as described previously (2), and dialyzed
extensively against phosphate-buffered saline (PBS). Purified L1/L2
capsids (1 mg) were incubated in 1 ml of PBS containing 2-ME (5%) for
16 h at 4°C to disassemble, under the conditions optimized by
McCarthy et al. for disassembly of HPV11 L1-capsids (7). The
disassembled capsids were mixed with ethanol-precipitated pSV/-gal
(2 mg), and the mixture was dialyzed against 4 liters of phosphate
buffer (pH 7.4) containing NaCl (0.5 M) and CaCl2 (2 mM)
for 24 h at 4°C. The solution was then centrifuged at 45,000 rpm
for 14 h in an NVT65.2 rotor (Beckman) after the density of the
solution was adjusted to 1.31 g/ml with PBS and CsCl. The resultant
gradient was fractionated (120 µl/fraction) for determination of
viral proteins and plasmid DNA.
View larger version (28K):
[in a new window]
FIG. 1.
(A) Distributions of L1 and L2 in CsCl equilibrium
density gradient centrifugation of reassembled HPV-16 L1/L2 capsids
were examined by ELISA using anti-L1 and anti-L2 antibodies. The ELISA
titer (optical density [OD] at 450 nm) for L1 ( 
) and for L2 (
)
of each fraction was plotted. (B) Plasmid DNA in fractions was examined
by PCR with primers specific for the -galactosidase gene and
template DNA extracted from the fractions with or without DNase I
digestion. An amplified DNA fragment (838 bp) was electrophoresed on a
1% agarose gel and stained with ethidium bromide. (C) The linear form
of pSV/-gal obtained by digestion with HindIII (lane
1), the closed circular form (lane 2), the open circular form obtained
by treatment with 10 units of topoisomerase I for 20 min at 37°C
(lane 3), pSV/-gal incubated in PBS containing 2-ME (5%) for
16 h at 4°C (lane 4), and DNA extracted from fraction 13 (lane
5) were electrophoresed on a 0.7% agarose gel and stained with
ethidium bromide.
-galactosidase gene. Ten-microliter aliquots of fractions 9 to 16 were diluted to 360 µl
with PBS containing 2.5 mM MgCl2 and digested with DNase I (250 U/ml) for 45 min at room temperature. For comparison, 10-µl aliquots of fractions 9 to 16 were similarly processed without DNase I. DNA extracted with phenol from the samples incubated with or without
DNase I was used as the template for PCR. With the DNase I-digested
samples, a DNA fragment with an expected size of 838 bp was amplified
only from fraction 13 (Fig. 1B), whereas DNA fragments were amplified
from all of the undigested fractions. Thus, it was concluded that
fraction 13 contained plasmid DNA resistant to digestion with DNase I. The form of DNA in fraction 13 was examined by agarose gel
electrophoresis (Fig. 1C). The mobility of phenol-extracted DNA from
DNase I-digested fraction 13 was compared with those of closed circular
(form I), open circular (form II), and linear (form III) DNA of
pSV/-gal. Both the DNA incubated in PBS containing 2-ME (5%) for
16 h at 4°C and the DNA extracted from fraction 13 showed
mobilities similar to that of open circular DNA. The DNA data (Fig.
1B), along with the protein data (Fig. 1A), strongly suggest that
fraction 13 (and probably fractions around 13) contained reassembled
HPV16 pseudovirions encapsidating plasmid DNA of the open circular form.
View larger version (82K):
[in a new window]
FIG. 2.
Electron microscopy of purified HPV-16 L1/L2 capsids
(A), disassembled capsids (B), and reassembled capsids (C). Bars, 100 nm.
The pseudovirions were examined for the capacity to mediate the
transfer of plasmid DNA to COS-1 cells. Fraction 13 was dialyzed against PBS to remove CsCl and incubated with COS-1 cells (4 × 105), which were dispersed with PBS containing EDTA (2.5 mM) and washed with Dulbecco's modified Eagle's medium in PBS (pH
6.8) containing bovine serum albumin (0.01%) for 2 h at 4°C
with constant agitation. The cells were seeded into six-well plates,
grown for 36 h, and fixed with glutaraldehyde. Cells expressing
-galactosidase were stained by using X-Gal
(5-bromo-4-chloro-3-indolyl--D-galactopyranoside) as the
substrate (In Situ -Galactosidase staining kit; Promega Corp.). The
number of blue cells was linearly dependent on the dilution of the
pseudovirions (Fig. 3A). Blue cells were
not detected in cells incubated with a mixture of L1/L2 capsid (50 ng)
and pSV/-gal (10 µg). DNase I treatment of the pseudovirions (50 ng), under conditions in which 20 µg of the plasmid was hydrolyzed completely in the presence of L1/L2 capsids (50 ng), did not reduce the
number of blue cells; 17 blue cells were detected. The efficiency of
DNA transfer by pseudovirions, approximately 50 blue cells per 200 ng
of L1 of fraction 13, was comparable to the HPV33 pseudovirions generated with a recombinant vaccinia virus (10). The
numbers of blue cells in CV-1 cell cultures infected with the
pseudovirions were less than 1/10 of those in COS-1 cultures,
indicating that autonomous replication of pSV/-gal mediated by
simian virus 40 T antigen was required for efficient detection of
infected cells.
|
) or mouse antiserum
diluted with PBS (indicated by, e.g., 1:100) and used to inoculate
COS-1 cells. Infectivity was indicated by the number of blue cells
(infectious unit) per ml.
Pseudovirion-mediated DNA transfer was inhibited by anti-HPV 16 L1/L2 or L1 antiserum (Fig. 3B). Pseudovirions were incubated at 4°C for 1 h with serial dilutions of a mouse antiserum obtained by immunizing BALB/c mice with L1/L2 (2) or L1 capsids (6) and then mixed with COS-1 cells, which were processed as described above. The numbers of blue cells were reduced by the antisera at dilutions of up to 1:1,000. Similarly prepared mouse antisera against HPV6 and HPV18 L1 capsids showed much weaker inhibitory effects on the transfer of DNA than did the anti-HPV16 antiserum (Fig. 3B), indicating that inhibition was specific to the HPV type.
Like HPV33 L1 capsids containing DNA (10), the HPV16
particles reassembled by the present procedure from L1 capsids and pSV/-gal were much less infectious (data not shown) than the reassembled L1/L2 pseudovirions. Thus, L2 appears to be required for
encapsidation of plasmids and/or expression of infectivity of virions.
In this study, we were able to reconstruct in vitro infectious HPV16 pseudovirions from purified and disassembled L1/L2 capsids and marker plasmid DNA. The reconstructed pseudovirions may be used for studies of the early events in HPV infection of cultured cells, because they are free of contaminating helper viruses. The fact that antiserum inhibition of DNA transfer is HPV-type specific provides a basis, with appropriate modifications of marker DNA and target cells in the present system, for development of a system to quantitate neutralizing antibodies of HPVs. It is also possible that packaging of plasmid DNA in vitro be used as a method to transfer exogenous genetic materials, which are protected from nucleases, to HPV-susceptible cells.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant-in-aid from the Ministry of Health and Welfare for the Second-Term Comprehensive 10-Year Strategy for Cancer Control and by a cancer research grant from the Ministry of Education, Science, and Culture.
We thank K. Suzuki for assistance in electron microscopy.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Molecular Genetics, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: 81-3-5285-1111, ext. 2524. Fax: 81-3-5285-1166. E-mail: kanda{at}nih.go.jp.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. |
Hagensee, M. E.,
N. H. Olson,
T. S. Baker, and D. A. Galloway.
1994.
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids.
J. Virol.
68:4503-4505 |
| 2. | Kawana, K., K. Matsumoto, H. Yoshikawa, Y. Taketani, T. Kawana, K. Yoshiike, and T. Kanda. 1998. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 245:353-359[Medline]. |
| 3. |
Kirnbauer, R.,
J. Taub,
H. Greenstone,
R. Roden,
M. Dürst,
L. Gissmann,
D. R. Lowy, and J. T. Schiller.
1993.
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.
J. Virol.
67:6929-6936 |
| 4. |
Li, M.,
P. Beard,
P. A. Estes,
M. K. Lyon, and R. L. Garcea.
1998.
Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly.
J. Virol.
72:2160-2167 |
| 5. | Lorincz, A. T., R. Reid, A. B. Jensen, M. D. Greenberg, A. W. Lancaster, and R. J. Kurman. 1991. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79:328-337. |
| 6. | Matsumoto, K., H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda. 1997. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn. J. Cancer Res. 88:369-375[Medline]. |
| 7. |
McCarthy, M. P.,
W. I. White,
F. Palmer-Hill,
S. Koenig, and J. A. Suzich.
1998.
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.
J. Virol.
72:32-41 |
| 8. |
Radloff, R.,
W. Bauer, and J. Vinograd.
1967.
A dye-buoyant-density method for the detection and isolation of closed circular duplex DNA: the closed circular DNA in HeLa cells.
Proc. Natl. Acad. Sci. USA
57:1514-1521 |
| 9. | Roden, R. B. S., H. L. Greenstone, R. Kirnbauer, F. P. Booy, J. Jessie, D. R. Lowy, and J. T. Schiller. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5878-5883. |
| 10. | Unckell, F., R. E. Streeck, and M. Sapp. 1997. Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71:2934-2939[Abstract]. |
| 11. |
Zhou, J.,
D. J. Stenzel,
X.-Y. Sun, and I. H. Frazer.
1993.
Synthesis and assembly of infectious bovine papillomavirus particles in vitro.
J. Gen. Virol.
74:763-768 |
| 12. |
Zhou, J.,
X.-Y. Sun,
K. Louis, and I. H. Frazer.
1994.
Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence.
J. Virol.
68:619-625 |
| 13. | zur Hausen, H. 1996. Papillomavirus infections a
major cause of human cancers. Biochim. Biophys. Acta
1288(Suppl. 2):F55-F78.
|
Journal of Virology, December 1998, p. 10298-10300, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Florin, L., Becker, K. A., Lambert, C., Nowak, T., Sapp, C., Strand, D., Streeck, R. E., Sapp, M.
(2006). Identification of a Dynein interacting domain in the papillomavirus minor capsid protein l2.. J. Virol.
80: 6691-6696
[Abstract] [Full Text] -
Kamper, N., Day, P. M., Nowak, T., Selinka, H.-C., Florin, L., Bolscher, J., Hilbig, L., Schiller, J. T., Sapp, M.
(2006). A Membrane-Destabilizing Peptide in Capsid Protein L2 Is Required for Egress of Papillomavirus Genomes from Endosomes. J. Virol.
80: 759-768
[Abstract] [Full Text] -
Huang, Y., Fayad, R., Smock, A., Ullrich, A. M., Qiao, L.
(2005). Induction of Mucosal and Systemic Immune Responses against Human Carcinoembryonic Antigen by an Oral Vaccine. Cancer Res.
65: 6990-6999
[Abstract] [Full Text] -
Patterson, N. A., Smith, J. L., Ozbun, M. A.
(2005). Human Papillomavirus Type 31b Infection of Human Keratinocytes Does Not Require Heparan Sulfate. J. Virol.
79: 6838-6847
[Abstract] [Full Text] -
Zhang, H., Fayad, R., Wang, X., Quinn, D., Qiao, L.
(2004). Human Immunodeficiency Virus Type 1 Gag-Specific Mucosal Immunity after Oral Immunization with Papillomavirus Pseudoviruses Encoding Gag. J. Virol.
78: 10249-10257
[Abstract] [Full Text] -
Fayad, R., Zhang, H., Quinn, D., Huang, Y., Qiao, L.
(2004). Oral Administration with Papillomavirus Pseudovirus Encoding IL-2 Fully Restores Mucosal and Systemic Immune Responses to Vaccinations in Aged Mice. J. Immunol.
173: 2692-2698
[Abstract] [Full Text] -
Florin, L., Becker, K. A., Sapp, C., Lambert, C., Sirma, H., Muller, M., Streeck, R. E., Sapp, M.
(2004). Nuclear Translocation of Papillomavirus Minor Capsid Protein L2 Requires Hsc70. J. Virol.
78: 5546-5553
[Abstract] [Full Text] -
Buck, C. B., Pastrana, D. V., Lowy, D. R., Schiller, J. T.
(2004). Efficient Intracellular Assembly of Papillomaviral Vectors. J. Virol.
78: 751-757
[Abstract] [Full Text] -
Yang, R., Yutzy, W. H. IV, Viscidi, R. P., Roden, R. B. S.
(2003). Interaction of L2 with beta -Actin Directs Intracellular Transport of Papillomavirus and Infection. J. Biol. Chem.
278: 12546-12553
[Abstract] [Full Text] -
Yang, R., Day, P. M., Yutzy, W. H. IV, Lin, K.-Y., Hung, C.-F., Roden, R. B. S.
(2003). Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection. J. Virol.
77: 3531-3541
[Abstract] [Full Text] -
Bousarghin, L., Touze, A., Sizaret, P.-Y., Coursaget, P.
(2003). Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells. J. Virol.
77: 3846-3850
[Abstract] [Full Text] -
Bousarghin, L., Touze, A., Combita-Rojas, A.-L., Coursaget, P.
(2003). Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J. Gen. Virol.
84: 157-164
[Abstract] [Full Text] -
Combita, A.-L., Touze, A., Bousarghin, L., Christensen, N. D., Coursaget, P.
(2002). Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses. J. Virol.
76: 6480-6486
[Abstract] [Full Text] -
Bousarghin, L., Combita-Rojas, A.-L., Touze, A., El Mehdaoui, S., Sizaret, P.-Y., Bravo, M.-M., Coursaget, P.
(2002). Detection of Neutralizing Antibodies against Human Papillomaviruses (HPV) by Inhibition of Gene Transfer Mediated by HPV Pseudovirions. J. Clin. Microbiol.
40: 926-932
[Abstract] [Full Text] -
Shi, W., Liu, J., Huang, Y., Qiao, L.
(2001). Papillomavirus Pseudovirus: a Novel Vaccine To Induce Mucosal and Systemic Cytotoxic T-Lymphocyte Responses. J. Virol.
75: 10139-10148
[Abstract] [Full Text] -
Fligge, C., Schafer, F., Selinka, H.-C., Sapp, C., Sapp, M.
(2001). DNA-Induced Structural Changes in the Papillomavirus Capsid. J. Virol.
75: 7727-7731
[Abstract] [Full Text] -
Kawana, Y., Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., Kanda, T.
(2001). Human Papillomavirus Type 16 Minor Capsid Protein L2 N-Terminal Region Containing a Common Neutralization Epitope Binds to the Cell Surface and Enters the Cytoplasm. J. Virol.
75: 2331-2336
[Abstract] [Full Text] -
Giroglou, T., Florin, L., Schäfer, F., Streeck, R. E., Sapp, M.
(2001). Human Papillomavirus Infection Requires Cell Surface Heparan Sulfate. J. Virol.
75: 1565-1570
[Abstract] [Full Text] -
Ishizu, K.-I., Watanabe, H., Han, S.-I., Kanesashi, S.-N., Hoque, M., Yajima, H., Kataoka, K., Handa, H.
(2001). Roles of Disulfide Linkage and Calcium Ion-Mediated Interactions in Assembly and Disassembly of Virus-Like Particles Composed of Simian Virus 40 VP1 Capsid Protein. J. Virol.
75: 61-72
[Abstract] [Full Text] -
El Mehdaoui, S., Touzé, A., Laurent, S., Sizaret, P.-Y., Rasschaert, D., Coursaget, P.
(2000). Gene Transfer Using Recombinant Rabbit Hemorrhagic Disease Virus Capsids with Genetically Modified DNA Encapsidation Capacity by Addition of Packaging Sequences from the L1 or L2 Protein of Human Papillomavirus Type 16. J. Virol.
74: 10332-10340
[Abstract] [Full Text] -
Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., Kanda, T.
(1999). Common Neutralization Epitope in Minor Capsid Protein L2 of Human Papillomavirus Types 16 and 6. J. Virol.
73: 6188-6190
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»